Total Payments
$2.1M
2024 Payments
$47,917
Companies
37
Transactions
1,807
Medicare Patients
9,697
Medicare Billing
$14.1M
Payment Breakdown by Category
Other$1.4M (66.5%)
Research$334,082 (15.8%)
Travel$208,617 (9.8%)
Consulting$127,337 (6.0%)
Food & Beverage$39,872 (1.9%)
Education$745.65 (0.0%)
Gifts$38.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.3M | 412 | 59.8% |
| Unspecified | $334,082 | 21 | 15.8% |
| Travel and Lodging | $208,617 | 409 | 9.8% |
| Honoraria | $139,817 | 50 | 6.6% |
| Consulting Fee | $127,337 | 55 | 6.0% |
| Food and Beverage | $39,872 | 840 | 1.9% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $2,400 | 2 | 0.1% |
| Education | $745.65 | 17 | 0.0% |
| Gift | $38.00 | 1 | 0.0% |
Payments by Type
General
$1.8M
1,786 transactions
Research
$334,082
21 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Amgen Inc. | $460,650 | 244 | $0 (2022) |
| E.R. Squibb & Sons, L.L.C. | $424,386 | 377 | $0 (2024) |
| GENZYME CORPORATION | $249,117 | 186 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $244,646 | 178 | $0 (2024) |
| Janssen Scientific Affairs, LLC | $171,345 | 137 | $0 (2024) |
| Karyopharm Therapeutics Inc. | $167,083 | 139 | $0 (2024) |
| Celgene Corporation | $151,061 | 115 | $0 (2024) |
| Janssen Biotech, Inc. | $127,065 | 175 | $0 (2024) |
| Millennium Pharmaceuticals, Inc. | $45,996 | 49 | $0 (2017) |
| AMAG Pharmaceuticals, Inc. | $41,811 | 49 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $47,917 | 80 | Janssen Biotech, Inc. ($22,282) |
| 2023 | $240,589 | 171 | Takeda Pharmaceuticals U.S.A., Inc. ($81,877) |
| 2022 | $170,785 | 140 | GENZYME CORPORATION ($57,589) |
| 2021 | $152,756 | 94 | GENZYME CORPORATION ($78,351) |
| 2020 | $83,261 | 83 | Karyopharm Therapeutics Inc. ($47,104) |
| 2019 | $349,230 | 370 | E.R. Squibb & Sons, L.L.C. ($119,274) |
| 2018 | $493,230 | 429 | Amgen Inc. ($188,393) |
| 2017 | $581,781 | 440 | Amgen Inc. ($186,773) |
All Payment Transactions
1,807 individual payment records from CMS Open Payments — Page 1 of 73
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/17/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $825.00 | General |
| Category: Oncology | ||||||
| 12/16/2024 | Janssen Biotech, Inc. | TECVAYLI (Biological), TALVEY | Food and Beverage | In-kind items and services | $25.57 | General |
| Category: Oncology | ||||||
| 12/11/2024 | Takeda Pharmaceuticals U.S.A., Inc. | NINLARO (Drug) | Food and Beverage | In-kind items and services | $28.44 | General |
| Category: ONCOLOGY | ||||||
| 12/08/2024 | Sebia Inc | — | Food and Beverage | Cash or cash equivalent | $29.09 | General |
| 12/06/2024 | PFIZER INC. | ELREXFIO (Drug) | Food and Beverage | In-kind items and services | $51.83 | General |
| Category: ONCOLOGY | ||||||
| 12/06/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $15.00 | General |
| 12/04/2024 | Karyopharm Therapeutics Inc. | XPOVIO (Drug) | Food and Beverage | In-kind items and services | $24.05 | General |
| Category: Oncology | ||||||
| 12/03/2024 | Cardinal Health 108 LLC | — | Food and Beverage | In-kind items and services | $41.58 | General |
| 11/21/2024 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $28.95 | General |
| Category: Hematology/Oncology | ||||||
| 11/20/2024 | PFIZER INC. | ELREXFIO (Drug) | Food and Beverage | In-kind items and services | $27.01 | General |
| Category: ONCOLOGY | ||||||
| 11/13/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $25.61 | General |
| Category: ONCOLOGY | ||||||
| 11/05/2024 | Takeda Pharmaceuticals U.S.A., Inc. | NINLARO (Drug) | Food and Beverage | In-kind items and services | $33.65 | General |
| Category: ONCOLOGY | ||||||
| 10/31/2024 | Celgene Corporation | Pomalyst (Drug) | Food and Beverage | Cash or cash equivalent | $18.46 | General |
| Category: Hematology | ||||||
| 10/30/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI, TALVEY | Food and Beverage | In-kind items and services | $22.69 | General |
| Category: Oncology | ||||||
| 10/29/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,860.00 | General |
| Category: Oncology | ||||||
| 10/23/2024 | PFIZER INC. | BOSULIF (Drug), ELREXFIO, ADCETRIS | Food and Beverage | In-kind items and services | $28.09 | General |
| Category: METABOLIC DISEASE;ONCOLOGY | ||||||
| 10/17/2024 | Janssen Biotech, Inc. | TECVAYLI (Biological), DARZALEX, TALVEY | Food and Beverage | In-kind items and services | $51.14 | General |
| Category: Oncology | ||||||
| 10/15/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $817.00 | General |
| Category: Oncology | ||||||
| 10/11/2024 | Karyopharm Therapeutics Inc. | XPOVIO (Drug) | Food and Beverage | In-kind items and services | $24.46 | General |
| Category: Oncology | ||||||
| 10/11/2024 | Karyopharm Therapeutics Inc. | XPOVIO (Drug) | Food and Beverage | In-kind items and services | $3.17 | General |
| Category: Oncology | ||||||
| 10/07/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,575.00 | General |
| Category: Oncology | ||||||
| 10/02/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI | Travel and Lodging | In-kind items and services | $558.25 | General |
| Category: Oncology | ||||||
| 10/01/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI | Food and Beverage | In-kind items and services | $150.00 | General |
| Category: Oncology | ||||||
| 09/25/2024 | Takeda Pharmaceuticals U.S.A., Inc. | NINLARO (Drug) | Food and Beverage | In-kind items and services | $30.17 | General |
| Category: ONCOLOGY | ||||||
| 09/24/2024 | Incyte Corporation | JAKAFI (Drug), NIKTIMVO | Food and Beverage | Cash or cash equivalent | $55.03 | General |
| Category: Hematology/Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| 4300 - CFZ Ph1b/2 CHAMPION #1 (2012-002) | Amgen Inc. | $118,335 | 4 |
| A PHASE 2, OPEN LABEL, RANDOMIZED TRIAL EVALUATING IXAZOMIB COMPARED TO IXAZOMIB-LENALIDOMIDE COMBINATION MAINTENANCE THERAPY FOR FRONTLINE MULTIPLE MYELOMA PATIENTS | Takeda Pharmaceuticals U.S.A., Inc. | $81,660 | 2 |
| Celgene - Connect MM | Celgene Corporation | $45,750 | 2 |
| Odex new formulations | Amgen Inc. | $39,951 | 4 |
| 6500 - OPZ Ph1b/3 OPomDex Study (OPZ 007) | Amgen Inc. | $21,288 | 2 |
| Ph3 Weekly Kd vs Kd (CFZ014) ARROW | Amgen Inc. | $5,108 | 2 |
| AMG 224 FIH Study In Multiple Myeloma | Amgen Inc. | $1,044 | 2 |
| AMG 982_Odex new formulations | Amgen Inc. | $587.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 43 | 2,416 | 344,458 | $12.8M | $3.9M |
| 2022 | 39 | 2,316 | 307,600 | $11.2M | $3.8M |
| 2021 | 44 | 2,478 | 273,772 | $10.8M | $3.4M |
| 2020 | 45 | 2,487 | 239,177 | $8.8M | $3.0M |
Total Patients
9,697
Total Services
1,165,007
Medicare Billing
$14.1M
Procedure Codes
171
All Medicare Procedures & Services
171 procedure records from CMS Medicare Utilization — Page 1 of 7
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9176 | Injection, elotuzumab, 1 mg | Office | 2023 | 18 | 155,303 | $1.2M | $859,116 | 69.2% |
| J9227 | Injection, isatuximab-irfc, 10 mg | Office | 2023 | 30 | 14,897 | $1.8M | $827,445 | 47.1% |
| J9047 | Injection, carfilzomib, 1 mg | Office | 2023 | 21 | 21,340 | $1.0M | $765,770 | 76.3% |
| J9144 | Injection, daratumumab, 10 mg and hyaluronidase-fihj | Office | 2023 | 12 | 8,349 | $645,841 | $314,526 | 48.7% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 28 | 14,775 | $354,240 | $259,635 | 73.3% |
| J9033 | Injection, bendamustine hcl (treanda), 1 mg | Office | 2023 | 13 | 17,047 | $841,610 | $177,697 | 21.1% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 66 | 1,064 | $558,600 | $126,812 | 22.7% |
| J9041 | Injection, bortezomib, 0.1 mg | Office | 2023 | 52 | 28,350 | $3.1M | $117,716 | 3.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 188 | 701 | $315,450 | $100,284 | 31.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 172 | 723 | $180,750 | $78,960 | 43.7% |
| 96409 | Administration of chemotherapy into vein using push technique | Office | 2023 | 46 | 658 | $242,144 | $59,994 | 24.8% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 90 | 1,987 | $278,180 | $51,724 | 18.6% |
| Q5106 | Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | Office | 2023 | 24 | 5,360 | $214,400 | $33,546 | 15.6% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 208 | 2,097 | $136,305 | $21,604 | 15.8% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 208 | 2,526 | $101,040 | $19,156 | 19.0% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 76 | 294 | $92,610 | $16,898 | 18.2% |
| 84165 | Protein measurement, serum | Office | 2023 | 205 | 1,596 | $119,475 | $16,678 | 14.0% |
| Q2050 | Injection, doxorubicin hydrochloride, liposomal, not otherwise specified, 10 mg | Office | 2023 | 11 | 196 | $262,798 | $15,151 | 5.8% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 23 | 183 | $25,071 | $12,194 | 48.6% |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | Office | 2023 | 22 | 28,560 | $75,113 | $11,381 | 15.2% |
| J3489 | Injection, zoledronic acid, 1 mg | Office | 2023 | 63 | 1,592 | $636,800 | $10,996 | 1.7% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 22 | 142 | $24,140 | $8,405 | 34.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 41 | 41 | $41,000 | $7,454 | 18.2% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 151 | 550 | $5,500 | $4,537 | 82.5% |
| 96411 | Administration of additional new drug or substance into vein using push technique | Office | 2023 | 15 | 83 | $30,544 | $4,210 | 13.8% |
About Dr. James Berenson, M.D
Dr. James Berenson, M.D is a Specialist healthcare provider based in West Hollywood, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/09/2006. The National Provider Identifier (NPI) number assigned to this provider is 1124051560.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. James Berenson, M.D has received a total of $2.1M in payments from pharmaceutical and medical device companies, with $47,917 received in 2024. These payments were reported across 1,807 transactions from 37 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($1.3M).
As a Medicare-enrolled provider, Berenson has provided services to 9,697 Medicare beneficiaries, totaling 1,165,007 services with total Medicare billing of $14.1M. Data is available for 4 years (2020–2023), covering 171 distinct procedure/service records.
Ad
Practice Information
- Specialty Specialist
- Other Specialties Research Study
- Location West Hollywood, CA
- Active Since 07/09/2006
- Last Updated 09/11/2025
- Taxonomy Code 174400000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1124051560
Products in Payments
- EMPLICITI (Biological) $376,994
- Kyprolis (Biological) $347,534
- DARZALEX (Biological) $290,523
- NINLARO (Drug) $285,714
- SARCLISA (Biological) $231,868
- XPOVIO (Drug) $167,083
- Revlimid (Drug) $142,514
- FERAHEME (Drug) $41,811
- XGEVA (Biological) $36,746
- Pomalyst (Drug) $33,518
- BLENREP (Biological) $18,693
- Kyprolis (Drug) $9,481
- CD38 (Drug) $8,819
- INJECTAFER (Drug) $6,097
- TECVAYLI (Biological) $5,459
- ELITEK (Drug) $4,998
- OPDIVO (Biological) $4,746
- EXKIVITY (Drug) $3,960
- VENCLEXTA (Drug) $3,399
- ABECMA (Biological) $2,070
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Specialist Doctors in West Hollywood
Ali Rezaie
Specialist — Payments: $756,521
Specialist $756,521
Dr. Ronald Natale, M.d, M.D
Specialist — Payments: $143,200
Specialist $143,200
Jean Marie Lopategui, Md, MD
Specialist — Payments: $62,778
Specialist $62,778
Dr. Ajay Ananda, M.d, M.D
Specialist — Payments: $29,911
Specialist $29,911
Cynthia Nast, Md, MD
Specialist — Payments: $21,213
Specialist $21,213
Dr. Shahram Naiem, M.d, M.D
Specialist — Payments: $18,079
Specialist $18,079